Drug intelligence / Profile preview

A19

Development stage: Preclinical
Lead developer: Shenyang Pharmaceutical University
Modality: Small Molecules

Overview

**A19** is a preclinical, covalent venetoclax-dihydroartemisinin conjugate developed by researchers at Shenyang Pharmaceutical University and the Samuel Waxman Institute for Aging and Cancer. It incorporates a polyethylene glycol linker intended to improve the aqueous solubility and antileukemic activity of earlier venetoclax-artemisinin conjugates. A19 retains B-cell lymphoma 2 inhibition associated with venetoclax and showed in vivo antitumor activity in acute myeloid leukemia models, with reported tumor-growth inhibition of 75.6%.

Targets

MCL1 (Myeloid cell leukemia sequence 1)

Beyond the preview

Go deeper on A19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A19.

Explore the full profile